On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened higher 3.22% from the last session, before settling in for the closing price of $4.66. Price fluctuations for RXRX have ranged from $3.79 to $12.36 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -35.28%. Company’s average yearly earnings per share was noted 7.30% at the time writing. With a float of $437.88 million, this company’s outstanding shares have now reached $485.21 million.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 15.91%, while institutional ownership is 48.90%. The most recent insider transaction that took place on Jan 06 ’26, was worth 959,200. In this transaction Director of this company sold 220,000 shares at a rate of $4.36, taking the stock ownership to the 6,649,863 shares. Before that another transaction happened on Jan 05 ’26, when Company’s Director sold 40,000 for $4.25, making the entire transaction worth $170,000. This insider now owns 933,839 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.53 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.42) by -0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.48% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 4.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 57.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.81, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.14 in one year’s time.
